Valneva (NASDAQ:VALN - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $17.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 149.45% from the stock's current price.
Valneva Stock Performance
Shares of VALN stock traded down $0.01 on Friday, reaching $6.82. The stock had a trading volume of 28,023 shares, compared to its average volume of 26,200. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $553.79 million, a price-to-earnings ratio of -52.42 and a beta of 1.98. The firm's 50-day moving average is $5.65 and its two-hundred day moving average is $5.66.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. ABC Arbitrage SA acquired a new stake in Valneva during the 4th quarter valued at $84,000. AlphaCentric Advisors LLC lifted its stake in shares of Valneva by 33.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company's stock worth $717,000 after buying an additional 29,748 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after buying an additional 30,859 shares during the period. 11.39% of the stock is currently owned by institutional investors.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
